FDA fates converge for BioMarin's drisapersen, Sarepta's eteplirsen
This article was originally published in Scrip
Executive Summary
It was always likely the fates of BioMarin Pharmaceutical's and Sarepta Therapeutics' experimental Duchenne muscular dystrophy (DMD) drugs were going to be bumping up against each other – although the former firm's product is a ahead of the latter in the regulatory process.